Approximately 80% of lung malignancies are non-small cell lung carcinoma (NSCLC). Patients diagnosed with early-stage disease (about 30% of patients) undergo surgery, but up to 50% develop local or distant recurrence. In an effort to improve survival for patients with resectable NSCLC, chemotherapy has been explored in the adjuvant setting. Several adjuvant trials were launched in the mid 1990s after an individual data-based meta-analysis suggested a 5% survival benefit at 5 years. Among those, the International Adjuvant Lung Cancer Trial (IALT) study, with 1,867 patients included, confirmed the benefit of postoperative chemotherapy in resected NSCLC. More recently, modern platinum-containing doublets showed a 10% to 15% overall benefit compared to no adjuvant treatment. In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed.

中文翻译：

---

早期非小细胞肺癌的辅助化疗。

大约80％的肺恶性肿瘤是非小细胞肺癌（NSCLC）。被诊断患有早期疾病的患者（约占患者的30％）接受手术治疗，但高达50％的患者会发生局部或远处复发。为了提高可切除NSCLC患者的生存率，已经在辅助治疗中探索了化学疗法。在一项基于数据的荟萃分析表明5年生存率提高5％之后，于1990年代中期启动了几项辅助试验。其中，国际辅助肺癌试验（IALT）研究纳入了1,867例患者，证实了手术切除的NSCLC对化疗的益处。最近，与未进行佐剂治疗相比，现代的含铂双峰化合物显示出10％至15％的总体收益。本文回顾了辅助化疗的现状，